Anti-CD38 interference with blood compatibility testing: Differentiating isatuximab and daratumumab via functional epitope mapping.

被引：0

作者：

Song, Zhili ^{[1
]}

Bedel, Olivier ^{[1
]}

Zhang, Bailin ^{[1
]}

Hopke, Joern ^{[2
]}

Deng, Gejing ^{[1
]}

Mace, Sandrine ^{[3
]}

Chiron, Marielle ^{[1
]}

Adrian, Francisco ^{[1
]}

Fukao, Taro ^{[1
]}

Basile, Frank ^{[1
]}

Pirenne, France ^{[4
]}

Okuda, Makoto ^{[5
]}

Moayeri, Morvarid ^{[6
]}

Chami, Btissam ^{[4
]}

Hidaka, Yoko ^{[5
]}

Nambiar, Ashok ^{[6
]}

Martin, Thomas ^{[7
]}

Zhu, Chen ^{[1
]}

机构：

[1] Sanofi Global Oncol, Cambridge, MA USA

[2] Sanofi Large Mol Res, Cambridge, MA USA

[3] Sanofi Res & Dev, Paris, France

[4] Etab Francais Sang Ile France, Paris, France

[5] Toho Univ, Med Ctr, Omori Hosp, Tokyo, Japan

[6] Univ Calif San Francisco, San Francisco, CA 94143 USA

[7] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1888

引用

页数：2